Auriga Upgrades Protalix BioTherapeutics (PLX) to Buy
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.44 +2.95%
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 1 | New: 16
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 1 | New: 16
Join SI Premium – FREE
Auriga upgraded Protalix BioTherapeutics (NYSE: PLX) from Hold to Buy, price target raised from $8 to $9.
For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.
Shares of Protalix BioTherapeutics closed at $6.73 yesterday.
For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.
Shares of Protalix BioTherapeutics closed at $6.73 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Upgrades Yangzijiang Shipbuilding (YZJSGD:SP) (YSHLF) to Neutral
- L&T Financial Holdings (LTFH:IN) PT Raised to INR380 at Axis Capital Limited
- Citi Downgrades ResMed (RMD:AU) (RMD) to Neutral
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesRelated Entities
AurigaSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
